Capricor Therap (CAPR) Stock Price, Quote & News

Company Profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial t...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 727 1755

Website: www.capricor.com

Address:

10865 Road to the Cure, Suite 150, San Diego, United States

Galaxy123 Jul. 19 at 6:47 PM

$CAPR Patent disputes take forever. Here is the summary of Arbutus patent dispute with Moderna and Pfizer Moderna Dispute • Feb 28, 2022: U.S. lawsuit filed • March 3, 2026: Global settlement announced Pfizer/BioNTech Dispute • April 4, 2023: U.S. lawsuit filed • Dec 2024: Claim construction hearing • Sept 9, 2025: Claim construction ruling • July 16, 2026: International lawsuits filed (Canada + Europe) Sarepta vs. NS Pharma (Nippon Shinyaku) Patent Dispute • July 13, 2021: NS Pharma sues Sarepta (Delaware) • Jan 2022: Sarepta files counterclaims (patent infringement) • May 1, 2024: Key court ruling on motions • Dec 19–20, 2024: Jury verdict — Sarepta wins ~$115M; NS patent invalidated

1 · Reply

clarksonhockey Jul. 19 at 6:47 PM

$CAPR Topline data from the HOPE-3 Phase III trial significantly addressed the FDA's previous concerns regarding deramiocel (CAP-1002) for Duchenne muscular dystrophy (DMD) cardiomyopathy. The trial successfully met both primary and secondary endpoints by showing statistically significant improvements in upper-limb function and dramatically slowing cardiac decline. Capricor Therapeutics resubmitted their Biologics License Application (BLA), and the FDA has set a target action date of August 22, 2026.Following the resubmission, the FDA scheduled an Advisory Committee meeting in late July 2026 to thoroughly review the clinical data. The data from the HOPE-3 study are unprecedented in largely non-ambulatory DMD populations, providing the regulatory agency with the substantial efficacy evidence they originally requested. Case closed! If FDA doesn't approve or ADCOM votes are not12-0. Somebody has an axe to grind!!

0 · Reply

Stormfury66 Jul. 19 at 6:03 PM

$CAPR It’s a NOTHING BURGER lawsuit & I don’t care what attorney or legal team it will take YEARS for an outcome . They simply want a piece of the CAPR pie upon FDA approval & it is coming my freind

1 · Reply

Traderbel1968 Jul. 19 at 5:58 PM

$CAPR Successful (!) companies get sued all the time. It is a great sign for CAPR that MESO comes out with this nonsense 2 weeks before the ADCOM while - in all these years - they have never been able to monetarze their own patents… What a joke.

0 · Reply

Stormfury66 Jul. 19 at 5:56 PM

$CAPR Thank you for the insight, as my attorney said it’s a NOTHING BURGER .. just the typical noise around CAPR prior to a BIG NEWS DROP

1 · Reply

Traderbel1968 Jul. 19 at 5:53 PM

$CAPR Don‘t waste ur valuable life and investing time with this MESO nonsense. Pure bs.

0 · Reply

NoMonkeyBusiness Jul. 19 at 4:52 PM

$CAPR Being a tax guy, I was educating myself on patent law to try to get a handle on this Mesoblast drama. An important rule is you CANNOT patent a naturally existing biological structure - there MUST be some kind of human intervention to produce something that is not naturally existing, and Capricor took care to make sure they complied with this. To survive this narrow requirement, Capricor Therapeutics (working with licensed technology from Cedars-Sinai Medical Center) secured "composition of matter" patents by defining very specific, non-naturally occurring formulations, structural parameters, or therapeutic combinations of CDC-exosomes paired with specific microRNAs for targeted tissue regeneration. GUT FEELING: This Mesoblast suit is nothing but a moonshot, probably orchestrated by NS.

4 · Reply

haha1978 Jul. 19 at 4:52 PM

$CAPR FBLG proccess derrived from skim cells also release exosomes so if they make it through their trials they will be next to get sued.

1 · Reply

haha1978 Jul. 19 at 4:49 PM

$CAPR also MESO will probably be suing everyone including the private companies and public on exosome excretion by cells. Goodluck to them wasting their money and time versus building a successful business. Maybe theirpatent will get over turned. Then they can go bankrupt.

0 · Reply

haha1978 Jul. 19 at 4:42 PM

$CAPR Biggest capr argument is to show the creation of exosomes are derrived from different proccesses and that a cell escection of an exosome is a natural process and not patentable to get thrown out. Adcom vote is in 2 weeks do you really want to miss a 100% plus pop on a yes vote? This close to approval ? Im going to hold. It could could go both ways but you cant patent natural proccesses and i dont see how a natural proccess such as exceting an exosomefrom a cell is patentable. MESO patents will now be reviewed and it will takes years to resolve. But wont stop capr at this point in time.

2 · Reply

Capricor announces FDA advisory committee meeting to review Deramiocel BLA

Jun 26, 2026, 10:02 AM EDT - 23 days ago

Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

2026-06-26T13:30:37.000Z - 23 days ago

Capricor presents five-year data from HOPE-2 open-label extension study

Jun 26, 2026, 9:05 AM EDT - 23 days ago

Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference

Jun 19, 2026, 5:47 PM EDT - 4 weeks ago

Caprock Announces Closing of Private Placement

Jun 17, 2026, 4:32 PM EDT - 4 weeks ago

Early Warning Press Release - Frank Guillemette Announces Completion of Acquisition of Common Shares of Caprock Mining Corp.

2026-06-16T18:45:26.000Z - 4 weeks ago

Capricor Therapeutics management to meet with Oppenheimer

Jun 12, 2026, 6:02 PM EDT - 5 weeks ago

Caprock Announces Proposed Private Placement

Jun 12, 2026, 5:40 PM EDT - 5 weeks ago

Caprock Announces Consistent High-Grade Intercepts from the Final Three Deep Drill Holes at Destiny, Including 8.32 g/t Au over 2.6m

Jun 10, 2026, 10:00 AM EDT - 5 weeks ago

Capricor Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 9:25 AM EDT - 5 weeks ago

Capricor Therapeutics to Present at Upcoming Investor Conferences

May 29, 2026, 7:00 AM EDT - 7 weeks ago

Capricor Therapeutics Slides: Corporate presentation

2026-05-15T02:55:10.000Z - 2 months ago

Capricor Therapeutics price target lowered to $38 from $43 at Roth Capital

May 12, 2026, 4:30 PM EDT - 2 months ago

Capricor Therapeutics Earnings Call Transcript: Q1 2026

May 12, 2026, 4:30 PM EDT - 2 months ago

Capricor Therapeutics Earnings release: Q1 2026

May 12, 2026, 4:30 PM EDT - 2 months ago

Capricor Therapeutics Quarterly report: Q1 2026

May 12, 2026, 4:05 PM EDT - 2 months ago

Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

2026-05-08T18:58:25.000Z - 2 months ago

Capricor files suit against NS Pharma over Deramiocel distribution deal

May 4, 2026, 4:05 PM EDT - 2 months ago

Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12

Apr 10, 2026, 8:00 AM EDT - 3 months ago

Capricor Therapeutics Proxy statement: Proxy filing

Mar 31, 2026, 8:00 AM EDT - 3 months ago

Capricor Therapeutics Proxy statement: Proxy filing

2026-03-20T12:45:14.000Z - 4 months ago

Capricor Therapeutics price target raised to $43 from $41 at Roth Capital

2026-03-13T18:35:53.000Z - 4 months ago

Capricor selloff today a buying opportunity, says Roth Capital

2026-03-13T16:01:07.000Z - 4 months ago

Capricor Therapeutics price target raised to $51 from $48 at Alliance Global

2026-03-13T12:27:39.000Z - 4 months ago

Capricor Therapeutics price target raised to $63 from $50 at B. Riley

2026-03-13T12:02:13.000Z - 4 months ago

Capricor Therapeutics price target raised to $58 from $45 at Piper Sandler

Mar 12, 2026, 4:30 PM EDT - 4 months ago

Capricor Therapeutics Earnings Call Transcript: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 4 months ago

Capricor Therapeutics Annual report: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 4 months ago

Capricor Therapeutics Earnings release: Q4 2025

2026-03-12T20:16:10.000Z - 4 months ago

Capricor Therapeutics reports Q4 EPS (62c), consensus (55c)

Mar 12, 2026, 4:01 PM EDT - 4 months ago

Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

2026-03-12T13:15:17.000Z - 4 months ago

Capricor announces additional analyses, outcomes from Phase 3 HOPE-3 trial

Mar 12, 2026, 9:00 AM EDT - 4 months ago

Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy

2026-03-10T13:38:59.000Z - 4 months ago

Capricor announces establishment of new PDUFA date for dermiocel BLA

Mar 10, 2026, 9:25 AM EDT - 4 months ago

Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA

Dec 17, 2025, 1:00 PM EST - 7 months ago

Capricor Therapeutics Transcript: Study Result

Dec 4, 2025, 4:01 PM EST - 8 months ago

Capricor Therapeutics Announces Proposed Public Offering of Common Stock

Dec 3, 2025, 11:30 AM EST - 8 months ago

Capricor Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 8:00 AM EST - 8 months ago

Capricor Therapeutics Transcript: Status Update

Dec 3, 2025, 8:00 AM EST - 8 months ago

Capricor Therapeutics Press release: Status Update

Dec 3, 2025, 8:00 AM EST - 8 months ago

Capricor Therapeutics Slides: Status Update

Dec 3, 2025, 7:44 AM EST - 8 months ago

Capricor's muscle disorder cell therapy succeeds in late-stage study

Nov 10, 2025, 4:30 PM EST - 8 months ago

Capricor Therapeutics Earnings Call Transcript: Q3 2025

Nov 10, 2025, 4:30 PM EST - 8 months ago

Capricor Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 4:30 PM EST - 8 months ago

Capricor Therapeutics Earnings release: Q3 2025

Nov 3, 2025, 9:15 AM EST - 9 months ago

Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel

Oct 31, 2025, 9:15 AM EDT - 9 months ago

Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10

Oct 13, 2025, 7:00 AM EDT - 9 months ago

Capricor Therapeutics Slides: Corporate Presentation

Oct 3, 2025, 10:45 AM EDT - 10 months ago

Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation

Sep 25, 2025, 8:30 AM EDT - 10 months ago

Capricor Therapeutics Transcript: Study Update

Sep 25, 2025, 8:30 AM EDT - 10 months ago

Capricor Therapeutics Press release: Study Update

Sep 25, 2025, 7:15 AM EDT - 10 months ago

Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting

Sep 10, 2025, 8:00 AM EDT - 11 months ago

Capricor Therapeutics Registration statement: Registration Filing

Sep 9, 2025, 9:20 AM EDT - 11 months ago

Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel

Aug 11, 2025, 4:30 PM EDT - 1 year ago

Capricor Therapeutics Earnings Call Transcript: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 1 year ago

Capricor Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 1 year ago

Capricor Therapeutics Earnings release: Q2 2025

Aug 8, 2025, 8:30 AM EDT - 1 year ago

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

Aug 6, 2025, 9:00 AM EDT - 1 year ago

Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13

Jul 14, 2025, 4:14 PM EDT - 1 year ago

Wolf Popper LLP Announces Investigation on Behalf of Capricor Therapeutics, Inc. Investors

Jul 11, 2025, 4:53 PM EDT - 1 year ago

Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura

Galaxy123 Jul. 19 at 6:47 PM

1 · Reply

clarksonhockey Jul. 19 at 6:47 PM

0 · Reply

Stormfury66 Jul. 19 at 6:03 PM

1 · Reply

Traderbel1968 Jul. 19 at 5:58 PM

0 · Reply

Stormfury66 Jul. 19 at 5:56 PM

$CAPR Thank you for the insight, as my attorney said it’s a NOTHING BURGER .. just the typical noise around CAPR prior to a BIG NEWS DROP

1 · Reply

Traderbel1968 Jul. 19 at 5:53 PM

$CAPR Don‘t waste ur valuable life and investing time with this MESO nonsense. Pure bs.

0 · Reply

NoMonkeyBusiness Jul. 19 at 4:52 PM

4 · Reply

haha1978 Jul. 19 at 4:52 PM

$CAPR FBLG proccess derrived from skim cells also release exosomes so if they make it through their trials they will be next to get sued.

1 · Reply

haha1978 Jul. 19 at 4:49 PM

0 · Reply

haha1978 Jul. 19 at 4:42 PM

2 · Reply

haha1978 Jul. 19 at 4:36 PM

$CAPR i could be wrong on MESO had patents before CAPR. But not worried about it. Its 2 disctinct proccesses of derriving the exosome. MESO patents will probably expire but they have 1000 patents starting in 2004 per ai and patented some process of causing the cells to excrete the exosomes. Not sure if that patent covers a natural process or not. But will good for the courts to review.

0 · Reply

haha1978 Jul. 19 at 4:26 PM

$CAPR Good luck in what ever longs decide to do sell or hold or buy.

1 · Reply

haha1978 Jul. 19 at 4:25 PM

$CAPR Also exosomes are natural. I dont see how you can patent ownership on a natural molecule. But you can patent mass production and proccess to maximize or produce exosomes artificially. This is a BS lawsuit and wont matter in the long run.

1 · Reply

haha1978 Jul. 19 at 4:22 PM

$CAPR Also CAPR owns the patents on mass producing exosomes MESO does not. CAPR is way ahead of the competition.

1 · Reply

haha1978 Jul. 19 at 4:22 PM

$CAPR @BioResearcher I think your wrong on this one. Ultimately CAPR discovered this before MESO and their exosomes are derived from heart not bone marrow. Regardless this wont stop the ADCOM from approving this drug with a yes vote. While i wanted to sell but ultimately im going to hold due to my tax situation this year and i promised to hold through approval and that vote is less than 2 weeks away. There will be multiple exosome lawsuits and they are similarly derived and can be derrived by multiple tissue types not just heart and bone but also fibroblast and any tissue as well. Look at FBLG exploring the skin cells. Granted its horrible management. You really dont need to taunt here with your alternative motives. Gene editing doesnt work. Srpt doesnt prevent cardiomyopathy. The only two choices you have is CAPR which is 3 years ahead of CPIX. And both of those are different mechanisms of action.

2 · Reply

NoSwagger Jul. 19 at 3:08 PM

$CAPR Is anyone expecting the peer-reviewed journal article this week? Time is off the essence, at least for SP.

3 · Reply

Andre_The_Giant Jul. 19 at 2:50 PM

$CAPR How did we end up living in an age when a bureaucrat is empowered to tell a dying man what he may or may not try to save his life, citing reasons such as “it may not be “effective” enough”?! Abolish the FDA and replace it with peer review panels of independent experts! Fire the bureaucrats and ban them from all classrooms! I would go as far as to say “burn ’em at the stake”, but we would want to conduct a clinical trial to determine if “it hurts bad enough”, which wouldn’t be worth the money.

1 · Reply

hatman547 Jul. 19 at 2:22 PM

$CAPR

0 · Reply

clarksonhockey Jul. 19 at 2:10 PM

$CAPR FDA get their answers plain and simple. Linda messed up with partner and this lawsuit tho! New CEO is warranted after approval!

1 · Reply

clarksonhockey Jul. 19 at 2:07 PM

$CAPR he pivotal Phase 3 HOPE-3 clinical trial demonstrated substantial, statistically significant evidence of effectiveness for Capricor Therapeutics' investigational cell therapy, Deramiocel (CAP-1002), in treating Duchenne muscular dystrophy (DMD).The study successfully met both its primary and key secondary endpoints:Skeletal Muscle Function: The trial met its primary endpoint by slowing the decline of upper-limb function (measured by the PUL v2.0 scale) by roughly 54% compared to the placebo over one year.Cardiac Function: The study's key secondary endpoint—preserving cardiac function as measured by left ventricular ejection fraction (LVEF)—reached statistical significance, slowing disease decline in the heart by 91% compared to the placebo.Disease Progression: Later data also showed that disease progression was slowed by approximately 83% according to the Duchenne Video Assessment (DVA).

1 · Reply

BioResearcher Jul. 19 at 1:57 PM

$CAPR Exactly, the Meso's lawuit can last for years, so it will overshadow IF any positive vote from ADCOM for years to come. Meso has a very strong case based on the filing. They are likely seek to block the drug from marketing if any positive result from ADCOM. Meso has very powerful lawyers, they will stop any illegal use of their technologies.

4 · Reply

Monkey7779192 Jul. 19 at 1:50 PM

$CAPR 3 or 35 to 40.

0 · Reply

Market Cap	1.13B
Revenue (ttm)	0.00
Net Income (ttm)	-105.04M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,165,200
Avg Vol	1,311,806
Day's Range	N/A - N/A
Shares Out	57.91M
Stochastic %K	18%
Beta	0.42
Analysts	Strong Sell
Price Target	$53.60